Broker Notes: Why analysts name TPG, Metcash and Actinogen to buy now?
$Actinogen Medical Ltd(ACW.AU$: Actinogen gets a speculative buy rating and A$0.09 target price as Bell Potter initiates coverage of the stock.
Australian biotech company following promising initial trial results for its lead cognitive-impairment drug candidate. Actinogen's Xanamem inhibits the enzyme that activates cortisol, high levels of which have been linked to diseases including Alzheimer's and major depression.
$TPG Telecom Ltd(TPG.AU$: UBS trims the target price by 2.8% to A$6.90 on higher interest-rate assumptions but maintains a buy rating on the stock.
TPG Telecom looks undervalued to UBS analyst Tom Beadle, who continues to believe the market is focused on near-term headwinds rather than long-term upside.
$Metcash Ltd(MTS.AU$: UBS maintains a buy rating and A$5.00 target price on the stock.
Metcash's FY 2022 results will show hardware sales rising by 16% on-year, UBS analyst Shaun Cousins predicts.
Australian biotech company following promising initial trial results for its lead cognitive-impairment drug candidate. Actinogen's Xanamem inhibits the enzyme that activates cortisol, high levels of which have been linked to diseases including Alzheimer's and major depression.
$TPG Telecom Ltd(TPG.AU$: UBS trims the target price by 2.8% to A$6.90 on higher interest-rate assumptions but maintains a buy rating on the stock.
TPG Telecom looks undervalued to UBS analyst Tom Beadle, who continues to believe the market is focused on near-term headwinds rather than long-term upside.
$Metcash Ltd(MTS.AU$: UBS maintains a buy rating and A$5.00 target price on the stock.
Metcash's FY 2022 results will show hardware sales rising by 16% on-year, UBS analyst Shaun Cousins predicts.
![Broker Notes: Why analysts name TPG, Metcash and Actinogen to buy now?](https://ussnsimg.moomoo.com/8281496953629145061.png/bigmoo)
Disclaimer: Moomoo Technologies Inc. is providing this content for information and educational use only.
Read more
Comment
Sign in to post a comment